Expert Consensus for Prevention, Diagnosis and Management of Persistent Chemotherapy-Induced Alopecia
September 2025
in “
PubMed
”

TLDR Prevent persistent hair loss after chemotherapy with scalp cooling and early minoxidil use.
Persistent chemotherapy-induced alopecia (pCIA) is a significant psychological burden for cancer survivors, yet lacks standardized guidelines. A Delphi study with 15 international experts achieved strong consensus on 47 statements, defining pCIA as non-scarring alopecia persisting beyond 6 months post-chemotherapy, primarily caused by the destruction of hair follicle stem cells due to agents like taxanes, thiotepa, and anthracyclines. Prevention through scalp cooling devices and early intervention with topical or low-dose oral minoxidil is recommended, while bicalutamide, oral finasteride, and dutasteride are not advised for breast cancer patients due to safety concerns. The study provides a framework for diagnosis and treatment, emphasizing prevention and early intervention, with further research needed on new treatments and long-term effects.